Skip to main content
SpringerLink
Log in

Oncolytic enteroviruses

  • Reviews
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

The growing body of knowledge concerning the molecular biology of viruses and virus-cell interactions provides possibilities to use viruses as a tool in an effort to treat malignant tumors. As a rule, tumor cells are highly sensitive to viruses, which can be used in cancer therapy. At the same time, the application of viral oncolysis in cancer treatment requires that the highest possible safety be ensured for both the patient and environment. Human enteroviruses are a convenient source for obtaining oncolytic virus strains, since many of them are nonpathogenic for humans or cause mild disease. The current progress in genetic engineering enables the development of attenuated enterovirus variants characterized with high safety and selectivity. This review focuses on the main members of the Enterovirus genus, such as ECHO, coxsackievirus, and vaccine strains of poliovirus as a promising source for the development of oncolytic agents applicable for cancer therapy. We have summarized the data concerning recently developed and tested oncolytic variants of enteroviruses and discusses the perspectives of their application in cancer therapy, as well as problems associated with their improvement and practical use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bernier J., Hall E.J., Giaccia A. 2004. Radiation oncology: A century of achievements. Nature Rev. Cancer. 4, 737–747.

    Article  CAS  Google Scholar 

  2. Farber S., Diamond L.K. 1948. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238, 787–793.

    Article  PubMed  CAS  Google Scholar 

  3. Pui C.H., Robison L.L., Look A.T. 2008. Acute lymphoblastic leukaemia. Lancet. 371, 1030–1043.

    Article  PubMed  CAS  Google Scholar 

  4. Bianchini C., Ciorba A., Pelucchi S., Piva R., Pastore A. 2011. Targeted therapy in head and neck cancer. Tumori. 97, 137–141.

    PubMed  CAS  Google Scholar 

  5. Litzow M.R. 2011. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs. 71, 415–442.

    PubMed  CAS  Google Scholar 

  6. Samant R.S., Shevde L.A. 2011. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2, 122–134.

    PubMed  Google Scholar 

  7. Dock G. 1904. The influence of complicating diseases upon leukemia. Am. J. Med. Sci. 127, 563–592.

    Google Scholar 

  8. De Pace N.G. 1912. Sulla scomparsa di un enorme cancro vegetante del callo dell’utero senza cura chirurgica. Ginecologia. 9, 82–86.

    Google Scholar 

  9. Levaditi C., Nicolau S. 1922. Sur la culture de virus vaccinal dans les neoplasmes epitheliaux. CR Soc. Biol. 85, 928.

    Google Scholar 

  10. Levaditi C., Nicolau S. 1922. Affinite du virus herpetique pour les neoplasmes epitheliaux. CR Soc. Biol. 87, 498–500.

    Google Scholar 

  11. Levaditi C., Nicolau S. 1923. Vaccine et neoplasmes. Ann. Inst. Pasteur. 37, 443–447.

    Google Scholar 

  12. Suskind R.G., Huebner R.J., Rowe W.P., Love R. 1957. Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses. Proc. Soc. Exp. Biol. Med. 94, 309–318.

    PubMed  CAS  Google Scholar 

  13. Bluming A.Z., Ziegler J.L. 1971. Regression of Burkitt’s lymphoma in association with measles infection. Lancet. 2, 105–106.

    Article  PubMed  CAS  Google Scholar 

  14. Sinkovics J., Horvath J. 1993. New developments in the virus therapy of cancer: A historical review. Intervirology. 36, 193–214.

    PubMed  CAS  Google Scholar 

  15. Lindenmann J., Klein P.A. 1967. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126, 93–108.

    Article  PubMed  CAS  Google Scholar 

  16. Kunin C.M. 1964. Cellular susceptibility to Enteroviruses. Bacteriol. Rev. 28, 382–390.

    PubMed  CAS  Google Scholar 

  17. Asada T. 1974. Treatment of human cancer with mumps virus. Cancer. 34, 1907–1928.

    Article  PubMed  CAS  Google Scholar 

  18. Southam C.M. 1960. Present status of oncolytic virus studies. Trans. NY Acad. Sci. 22, 657–673.

    Article  CAS  Google Scholar 

  19. Moore A.E. 1952. Viruses with oncolytic properties and their adaptation to tumors. Ann. NY Acad. Sci. 54, 945–952.

    Article  PubMed  CAS  Google Scholar 

  20. Moore A.E. 1954. Effects of viruses on tumors. Annu. Rev. Microbiol. 8, 393–410.

    Article  PubMed  CAS  Google Scholar 

  21. Newman W., Southam C.M. 1954. Virus treatment in advanced cancer A pathological study of fifty-seven cases. Cancer. 7, 106–118.

    Article  PubMed  CAS  Google Scholar 

  22. Voroshilova M.K., Chumakov M.P., Koroleva G.A., Grachev V.P., Lavrova I.K., Alpatova G.A., Umanskii K.G., Vaganova N.T., Rozenbaum G.I., Chartseva V.F., Rabinovich E.A., Sinyak L.I., Lukina V.A., Chichel’nitskii D.I., 1969. Continued observations on the safety and oncolytic activity of some enterovirus vaccines administered in massive dosage to patients with oncological diseases. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, p. 69.

  23. Kuruppu D., Tanabe K.K. 2005. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther. 4, 524–531.

    Article  PubMed  CAS  Google Scholar 

  24. Everts B., van der Poel H.G. 2005. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12, 141–161.

    Article  PubMed  CAS  Google Scholar 

  25. Power A.T., Bell J.C. 2008. Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther. 15, 772–779.

    Article  PubMed  CAS  Google Scholar 

  26. Verheije M.H., Rottier J.M. 2012. Retargeting of viruses to generate oncolytic agents. Adv. Virol. ID 798526.

  27. Mohr I. 2005. To replicate or not to replicate: Achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene. 24, 7697–7709.

    Article  PubMed  CAS  Google Scholar 

  28. Dobbelstein M. 2004. Replicating adenoviruses in cancer therapy. Curr. Top. Microbiol. Immunol. 273, 291–334.

    PubMed  CAS  Google Scholar 

  29. Voroshilova M.K. 1979. Enterovirusnye infektsii cheloveka (Human Enteroviral Infections). Moscow: Meditsina.

    Google Scholar 

  30. Pallansch M., Roos R. 2007. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and newer Enteroviruses. In: Fields Virology. Eds. Knipe D.M., Howley P.M. Philadelphia: Lippincott Williams & Wilkins, pp. 840–893.

    Google Scholar 

  31. Flanegan J.B., Petterson R.F., Ambros V., Hewlett N.J., Baltimore D. 1977. Covalent linkage of a protein to a defined nucleotide sequence at the 5′-terminus of virion and replicative intermediate RNAs of poliovirus. Proc. Natl. Acad. Sci. U. S. A. 74, 961–965.

    Article  PubMed  CAS  Google Scholar 

  32. Lee Y.F., Nomoto A., Detjen B.M., Wimmer E. 1977. A protein covalently linked to poliovirus genome RNA. Proc. Natl. Acad. Sci. U. S. A. 74, 59–63.

    Article  PubMed  CAS  Google Scholar 

  33. Duke G.M., Osorio J.E., Palmenberg A.C. 1990. Attenuation of Mengo virus through genetic engineering of the 5′ noncoding poly(C) tract. Nature. 343, 474–476.

    Article  PubMed  CAS  Google Scholar 

  34. Hahn H., Palmenberg A.C. 1995. Encephalomyocarditis viruses with short poly(C) tracts are more virulent than their mengovirus counterparts. J. Virol. 69, 2697–2699.

    PubMed  CAS  Google Scholar 

  35. Todd S., Towner J.S., Brown D.M., Semler B.L. 1997. Replication-competent picornaviruses with complete genomic RNA 3′ noncoding region deletions. J. Virol. 71, 8868–8874.

    PubMed  CAS  Google Scholar 

  36. Spector D.H., Baltimore D. 1974. Requirement of 3′-terminal poly(adenylic acid) for the infectivity of poliovirus RNA. Proc. Natl. Acad. Sci. U. S. A. 71, 2983–2987.

    Article  PubMed  CAS  Google Scholar 

  37. Jarvis T.C., Kirkegaard K. 1992. Poliovirus RNA recombination: Mechanistic studies in the absence of selection. EMBO J. 11, 3135–3145.

    PubMed  CAS  Google Scholar 

  38. Summers D.F., Maizel J.V., Jr. 1968. Evidence for large precursor proteins in poliovirus synthesis. Proc. Natl. Acad. Sci. U. S. A. 59, 966–971.

    Article  PubMed  CAS  Google Scholar 

  39. Ward T., Powell R.M., Pipkin P.A., Evans D.J., Minor P.D., Almond J.W. 1998. Role for beta2-microglobulin in echovirus infection of rhabdomyosarcoma cells. J. Virol. 72, 5360–5365.

    PubMed  CAS  Google Scholar 

  40. Shafren D.R. 1998. Viral cell entry induced by crosslinked decay-accelerating factor. J. Virol. 72, 9407–9412.

    PubMed  CAS  Google Scholar 

  41. Shafren D.R., Dorahy D.J., Ingham R.A., Burns G.F., Barry R.D. 1997. Coxsackievirus A21 binds to decayaccelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 71, 4736–4743.

    PubMed  CAS  Google Scholar 

  42. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., Finberg R.W. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275, 1320–1323.

    Article  PubMed  CAS  Google Scholar 

  43. Carson S.D., Chapman N.N., Tracy S.M. 1997. Purification of the putative Coxsackievirus B receptor from HeLa cells. Biochem. Biophys. Res. Commun. 233, 325–328.

    Article  PubMed  CAS  Google Scholar 

  44. Tomko R.P., Xu R., Philipson L. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U. S. A. 94, 3352–3356.

    Article  PubMed  CAS  Google Scholar 

  45. Mendelsohn C.L., Wimmer E., Racaniello V.R. 1989. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 56, 855–865.

    Article  PubMed  CAS  Google Scholar 

  46. Jenista J.A., Powell K.R., Menegus M.A. 1984. Epidemiology of neonatal enterovirus infection. J. Pediatr. 104, 685–690.

    Google Scholar 

  47. Muir P., Kämmerer U., Korn K., Mulders M.N., Pöyry T., Weissbrich B., Kandolf R., Cleator G.M., van Loon A.M. 1998. Molecular typing of enteroviruses: Current status and future requirements. The European Union concerted action on virus meningitis and encephalitis. Clin. Microbiol. Rev. 11, 202–227.

    PubMed  CAS  Google Scholar 

  48. Lashkevich V.A., Koroleva G.A., Lukashev A.N., Denisova E.V., Katargina L.A. 2004. Enterovirus uveitis. Rev. Med. Virol. 14, 241–254.

    Article  PubMed  Google Scholar 

  49. Lukashev A.N., Lashkevich V.A., Koroleva G.A., Ilonen J., Karganova G.G., Reznik V.I., Hinkkanen A.E. 2003. Molecular epidemiology of enteroviruses causing uveitis and multisystem hemorrhagic disease of infants. Virology. 307, 45–53.

    Article  PubMed  CAS  Google Scholar 

  50. el-Sageyer M.M., Szendröi A., Hütter E., Uj M., Szücs G., Mezey I., Tóth I., Kátai A., Kapiller Z., Páll G., Petrás G., Szalay E., Mihály I., Gourova S., Berencsi G. 1998. Characterisation of an echovirus type 11’ (prime) epidemic strain causing haemorrhagic syndrome in newborn babies in Hungary. Acta Virol. 42, 157–166.

    PubMed  CAS  Google Scholar 

  51. Rabkin C.S., Telzak E.E., Ho M.S., Goldstein J., Bolton Y., Pallansch M., Anderson L., Kilchevsky E., Solomon S., Martone W.J. 1988. Outbreak of echovirus 11 infection in hospitalized neonates. Pediatr. Infect. Dis. J. 7, 186–190.

    PubMed  CAS  Google Scholar 

  52. Voroshilova M.K. 1989. Potential use of nonpathogenic enteroviruses for control of human disease. Prog. Med. Virol. 36, 191–202.

    PubMed  CAS  Google Scholar 

  53. Voroshilova M.K. 1988. Virological and immunological aspects of administration of live enteroviral vaccines in oncological diseases. In: Poleznye dlya ogranizma nepatogennye shtammy enterovirusov: profilakticheskoe i lechebnoe ikh primenenie (Useful Nonpathogenic Enterovirus Strains: Preventive and Therapeutic Applications). Moscow: Meditsina, pp. 24–29.

    Google Scholar 

  54. Voroshilova M.K. 1977. Evolution of enteroviral infections. Vestn. Akad. Med. Nauk SSSR. 42–50.

  55. Au G.G., Beagley L.G., Haley E.S., Barry R.D., Shafren D.R. 2011. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol. J. 8, 22.

    Article  PubMed  CAS  Google Scholar 

  56. Taylor M.W., Cordell B., Souhrada M., Prather S. 1971. Viruses as an aid to cancer therapy: Regression of solid and ascites tumors in rodents after treatment with bovine enterovirus. Proc. Natl. Acad. Sci. U. S. A. 68, 836–840.

    Article  PubMed  CAS  Google Scholar 

  57. Berry L.J., Au G.G., Barry R.D., Shafren D.R. 2008. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate. 68, 577–587.

    Article  PubMed  Google Scholar 

  58. Haley E.S., Au G.G., Carlton B.R., Barry R.D., Shafren D.R. 2009. Regional administration of oncolytic echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer. J. Mol. Med. 87, 385–399.

    Article  PubMed  Google Scholar 

  59. Muceniece A.J. 1978. Analysis of sensitivity of human melanomas to enteroviruses adaptred to these tumors. In: Virusy v terapii opukholei (Viruses in Antitumor Therapy), Riga: Zinatne, pp. 175–189.

    Google Scholar 

  60. Dobrikova E.Y., Broadt T., Poiley-Nelson J., Yang X., Soman G., Giardina S., Harris R., Gromeier M. 2008. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 16, 1865–1872.

    Article  PubMed  CAS  Google Scholar 

  61. Gromeier M., Lachmann S., Rosenfeld M.R., Gutin P.H., Wimmer E. 2000. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 97, 6803–6808.

    Article  PubMed  CAS  Google Scholar 

  62. Toyoda H., Ido M., Hayashi T., Gabazza E.C., Suzuki K., Kisenge R.R., Kang J., Hori H., Komada Y. 2004. Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int. J. Oncol. 24, 49–58.

    PubMed  Google Scholar 

  63. Toyoda H., Wimmer E., Cello J. 2011. Oncolytic poliovirus therapy and immunization with poliovirusinfected cell lysate induces potent antitumor immunity against neuroblastoma in vivo. Int. J. Oncol. 38, 81–87.

    PubMed  Google Scholar 

  64. Au G.G., Lincz L.F., Enno A., Shafren D.R. 2007. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br. J. Haematol. 137, 133–141.

    Article  PubMed  CAS  Google Scholar 

  65. Au G.G., Lindberg A.M., Barry R.D., Shafren D.R. 2005. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int. J. Oncol. 26, 1471–1476.

    PubMed  CAS  Google Scholar 

  66. Skelding K.A., Barry R.D., Shafren D.R. 2009. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res. Treat. 113, 21–30.

    Article  PubMed  Google Scholar 

  67. Chumakov M.P., Voroshilova M.K., Antsupova A.S., Boiko V.M., Blinova M.I., Priimyagi L.S., Rodin V.I., Seibil’ V.B., Sinyak K.M., Smorodintsev A.A., Stepanchuk V.A., Terekhov S.N., Trofimova L.I., Chumakov P.M. 1992. Live enteroviral vaccines for urgent preventive therapy against respiratory diseases during autumn-winter epidemics of influenza and acute respiratory diseases. Zh. Mikrobiol. Epidemiol. Infekts. Dis. 37–40.

  68. Voroshilova M.K., Tol’skaya E.A., Koroleva G.A., Chumakov K.M., Chumakov, P.M. 1970. Studies on biological and morphological properties of viruses ECHO-1 and ECHO-12. In: Enterovirusnye infektsii (Enteroviral Infections). Tr. Inst. Poliom. Virus. Entsef. Akad. Med. Nauk SSSR. Moscow, pp. 269–274.

  69. Koroleva G.A., Voroshilova M.K., Grachev V.P. 1969. Biological properties of enteroviral vaccine strains ZhEV-4, ZhEV-7, ZhEV11, and ZhEV-13. Materialy 16 nauchnoi sessii instituta poliomielita i virusnykh entsefalitov (Proc. 16th Sci. Session of the Institute of Poliomyelitis and Viral Encephalitides), Moscow, p. 185.

  70. Chumakov M.P., Voroshilova M.K., Boiko V.M. 1973. On the results of large-scale controlled trials for epidemiological efficiency of live enterovirus vaccines for urgent preventive treatment against influenza and viral acute respiratory diseases. Tr. Inst. Poliom. Virus. Entsef. Akad. Med. Nauk SSSR. Moscow, pp. 19–28.

  71. Voroshilova M.K., Baganova N.T. 1969. Experience in treating patients with gastrointestinal tumors by live enterovirus vaccines. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 23–26

  72. Tsypkin L.B., Voroshilova M.K., Goryunova A.G., Lavrova I.K., Koroleva G.A. 1976. The morphology of tumors of the human gastrointestinal tract in shortterm organ culture and the reaction of these tumors to infection with poliovirus. Cancer. 38, 1796–1806.

    Article  PubMed  CAS  Google Scholar 

  73. Voroshilova M.K., Goryunova A.G., Gorbachkova E.A., Chumakov P.M., Oganyan G.R., Kodkind G.H. 1977. Studies on cellular immunity of oncological patients in the course of asymptomatic enteroviral infection. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 17–19.

  74. Voroshilova M.K., Magazanik S.S., Chumakov P.M., 1980. Useful human viruses. In: Aktual’nye voprosy epidemiologii, mikrobiologii i infektsionnykh zabolevanii (Current Problems of Epidemiology, Microbiology, and Infectious Diseases), Tashkent: Meditsina, pp. 227–229.

    Google Scholar 

  75. Muceniece A.J. 1972. Onkotropizm virusov i problema viroterapii zlokachestvennykh opukholei (Oncotropism of Viruses and the Problem of Viral Therapy against Malignant Tumors). Riga: Zinatne.

    Google Scholar 

  76. Muceniece A.J., Bumbieris J.V. 1982. Transplantation antigens and their changes in carcinogenesis and viral infection. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 217–234.

  77. Priedite I.J., Garklava R.R., Muceniece A.J. 1971. Treatment of patients with gastric cancer after palliative surgery. Materialy III konferentsii onkologov ESSR, LitSSR i LatvSSR (Proc. III Conf. of Estonian, Lithuanian, and Latvian Oncologists), Riga, p. 77.

  78. Shafren D.R., Sylvester D., Johansson E.S., Campbell I.G., Barry R.D. 2005. Oncolysis of human ovarian cancers by echovirus type 1. Int. J. Cancer. 115, 320–328.

    Article  PubMed  CAS  Google Scholar 

  79. Bergelson J.M., Shepley M.P., Chan B.M., Hemler M.E., Finberg R.W. 1992. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science. 255, 1718–1720.

    Article  PubMed  CAS  Google Scholar 

  80. King S.L., Cunningham J.A., Finberg R.W., Bergelson J.M. 1995. Echovirus 1 interaction with the isolated VLA-2 I domain. J. Virol. 69, 3237–3239.

    PubMed  CAS  Google Scholar 

  81. Moser T.L., Pizzo S.V., Bafetti L.M., Fishman D.A., Stack M.S. 1996. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int. J. Cancer. 67, 695–701.

    Article  PubMed  CAS  Google Scholar 

  82. Bartolazzi A., Kaczmarek J., Nicolo G., Risso A.M., Tarone G., Rossino P., Defilippi P., Castellani P. 1993. Localization of the alpha 3 beta 1 integrin in some common epithelial tumors of the ovary and in normal equivalents. Anticancer Res. 13, 1–11.

    PubMed  CAS  Google Scholar 

  83. Buczek-Thomas J.A., Chen N., Hasan T. 1998. Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal. 10, 55–63.

    Article  PubMed  CAS  Google Scholar 

  84. Cannistra S.A., Ottensmeier C., Niloff J., Orta B., DiCarlo J. 1995. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol. Oncol. 58, 216–225.

    Article  PubMed  CAS  Google Scholar 

  85. Koike N., Todoroki T., Komano H., Shimokama T., Ban S., Ohno T., Fukao K., Watanabe T. 1997. Invasive potentials of gastric carcinoma cell lines: role of alpha 2 and alpha 6 integrins in invasion. J. Cancer Res. Clin. Oncol. 123, 310–316.

    PubMed  CAS  Google Scholar 

  86. Jokinen J., White D.J., Salmela M., Huhtala M., Kapyla J., Sipila K., Puranen J.S., Nissinen L., Kankaanpaa P., Marjomaki V., Hyypia T., Johnson M.S., Heino J. 2010. Molecular mechanism of alpha2beta1 integrin interaction with human echovirus 1. EMBO J. 29, 196–208.

    Article  PubMed  CAS  Google Scholar 

  87. Bianco A., Whiteman S.C., Sethi S.K., Allen J.T., Knight R.A., Spiteri M.A. 2000. Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial cells of atopic subjects: A mechanism for increased rhinovirus infection? Clin. Exp. Immunol. 121, 339–345.

    Article  PubMed  CAS  Google Scholar 

  88. Lublin D.M., Atkinson J.P. 1989. Decay-accelerating factor: Biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7, 35–58.

    Article  PubMed  CAS  Google Scholar 

  89. Rosette C., Roth R.B., Oeth P., Braun A., Kammerer S., Ekblom J., Denissenko M.F. 2005. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 26, 943–950.

    Article  PubMed  CAS  Google Scholar 

  90. Shafren D.R., Au G.G., Nguyen T., Newcombe N.G., Haley E.S., Beagley L., Johansson E.S., Hersey P., Barry R.D. 2004. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 10, 53–60.

    Article  PubMed  CAS  Google Scholar 

  91. Skelding K.A., Barry R.D., Shafren D.R. 2010. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest. New Drugs. 21, 21.

    Google Scholar 

  92. Wodarz D. 2001. Viruses as antitumor weapons: Defining conditions for tumor remission. Cancer Res. 61, 3501–3507.

    PubMed  CAS  Google Scholar 

  93. Mueller S., Wimmer E., Cello J. 2005. Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental event. Virus Res. 111, 175–193.

    Article  PubMed  CAS  Google Scholar 

  94. Dobrikova E., Florez P., Bradrick S., Gromeier M. 2003. Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3′ nontranslated region. Proc. Natl. Acad. Sci. U. S. A. 100, 15125–15130.

    Article  PubMed  CAS  Google Scholar 

  95. Toyoda H., Yin J., Mueller S., Wimmer E., Cello J. 2007. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirussusceptible animal model. Cancer Res. 67, 2857–2864.

    Article  PubMed  CAS  Google Scholar 

  96. Gromeier M., Solecki D., Patel D.D., Wimmer E. 2000. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology. 273, 248–257.

    Article  PubMed  CAS  Google Scholar 

  97. Solecki D., Bernhardt G., Lipp M., Wimmer E. 2000. Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. J. Biol. Chem. 275, 12453–12462.

    Article  PubMed  CAS  Google Scholar 

  98. Solecki D., Wimmer E., Lipp M., Bernhardt G. 1999. Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J. Biol. Chem. 274, 1791–1800.

    Article  PubMed  CAS  Google Scholar 

  99. Solecki D.J., Gromeier M., Mueller S., Bernhardt G., Wimmer E. 2002. Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J. Biol. Chem. 277, 25697–25702.

    Article  PubMed  CAS  Google Scholar 

  100. Ochiai H., Moore S.A., Archer G.E., Okamura T., Chewning T.A., Marks J.R., Sampson J.H., Gromeier M. 2004. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin. Cancer Res. 10, 4831–4838.

    Article  PubMed  CAS  Google Scholar 

  101. Ansardi D.C., Porter D.C., Anderson M.J., Morrow C.D. 1996. Poliovirus assembly and encapsidation of genomic RNA. Adv. Virus Res. 46, 1–68.

    Article  PubMed  CAS  Google Scholar 

  102. Ansardi D.C., Porter D.C., Jackson C.A., Gillespie G.Y., Morrow C.D. 2001. RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res. 61, 8470–8479.

    PubMed  CAS  Google Scholar 

  103. Porter D.C., Ansardi D.C., Morrow C.D. 1995. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans. J. Virol. 69, 1548–1555.

    PubMed  CAS  Google Scholar 

  104. Porter D.C., Melsen L.R., Compans R.W., Morrow C.D. 1996. Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J. Virol. 70, 2643–2649.

    PubMed  CAS  Google Scholar 

  105. Solecki D., Schwarz S., Wimmer E., Lipp M., Bernhardt G. 1997. The promoters for human and monkey poliovirus receptors: Requirements for basic and cell type-specific activity. J. Biol. Chem. 272, 5579–5586.

    Article  PubMed  CAS  Google Scholar 

  106. Goetz C., Gromeier M. 2010. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev. 21, 197–203.

    Article  PubMed  CAS  Google Scholar 

  107. Merrill M.K., Dobrikova E.Y., Gromeier M. 2006. Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J. Virol. 80, 3147–3156.

    Article  PubMed  CAS  Google Scholar 

  108. Merrill M.K., Gromeier M. 2006. The doublestranded RNA binding protein 76: NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J. Virol. 80, 6936–6942.

    Article  PubMed  CAS  Google Scholar 

  109. Ochiai H., Campbell S.A., Archer G.E., Chewning T.A., Dragunsky E., Ivanov A., Gromeier M., Sampson J.H. 2006. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin. Cancer Res. 12, 1349–1354.

    Article  PubMed  CAS  Google Scholar 

  110. De Jesus N., Franco D., Paul A., Wimmer E., Cello J. 2005. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J. Virol. 79, 14235–14243.

    Article  PubMed  CAS  Google Scholar 

  111. Paul A.V. 2002. Possible unifying mechanism of picornavirus genome replication. In: Molecular Biology of Picornaviruses. Eds. Semler B.L., Wimmer E. Washington, DC: ASM Press, pp. 227–246.

    Google Scholar 

  112. Yin J., Paul A.V., Wimmer E., Rieder E. 2003. Functional dissection of a poliovirus cis-acting replication element [PV-cre(2C)]: Analysis of single- and dualcre viral genomes and proteins that bind specifically to PV-cre RNA. J. Virol. 77, 5152–5166.

    Article  PubMed  CAS  Google Scholar 

  113. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W. 1998. Reovirus therapy of tumors with activated Ras pathway. Science. 282, 1332–1334.

    Article  PubMed  CAS  Google Scholar 

  114. Nakamura H., Kasuya H., Mullen J.T., Yoon S.S., Pawlik T.M., Chandrasekhar S., Donahue J.M., Chiocca E.A., Chung R.Y., Tanabe K.K. 2002. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. 109, 871–882.

    PubMed  CAS  Google Scholar 

  115. Nemunaitis J., Ganly I., Khuri F., Arseneau J., Kuhn J., McCarty T., Landers S., Maples P., Romel L., Randlev B., Reid T., Kaye S., Kirn D. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 60, 6359–6366.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Novosibirsk State University, Novosibirsk, 630090, Russia

    P. M. Chumakov, V. V. Morozova, I. V. Babkin, I. K. Baikov, S. V. Netesov & N. V. Tikunova

  2. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia

    P. M. Chumakov

  3. Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

    P. M. Chumakov

  4. Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia

    V. V. Morozova, I. V. Babkin, I. K. Baikov & N. V. Tikunova

  5. Vector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk region, 630559, Russia

    S. V. Netesov

Authors
  1. P. M. Chumakov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. V. Morozova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. V. Babkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. K. Baikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. V. Netesov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. V. Tikunova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. V. Tikunova.

Additional information

Original Russian Text © P.M. Chumakov, V.V. Morozova, I.V. Babkin, I.K. Baikov, S.V. Netesov, N.V. Tikunova, 2012, published in Molekulyarnaya Biologiya, 2012, Vol. 46, No. 5, pp. 712–725.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chumakov, P.M., Morozova, V.V., Babkin, I.V. et al. Oncolytic enteroviruses. Mol Biol 46, 639–650 (2012). https://doi.org/10.1134/S0026893312050032

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893312050032

Keywords

Search

Navigation